Parkinson's disease-derived α-synuclein assemblies combined with chronic-type inflammatory cues promote a neurotoxic microglial phenotype.

"Declarations Ethics approval and consent to participateThe protocol used for collecting human peripheral blood mononuclear cells was approved by an ethical committee affiliated with French regulation authorities (CCPPRB Groupe Hospitalier Pitié-Salpêtrière, Paris, France). Blood samples were collected from a donor who provided signed informed consent and who was included in an INSERM-sponsored clinical study. Experimental procedures in mice were authorized by the Committee on the Ethics of Animal Experiments Charles Darwin No. 5 under the registration number Ce5/2017/005. Consent for publicationNot applicable. Competing interestsThe authors declare that there are no conflicts of interest regarding the experimental part of this study. Competing interests The authors declare that there are no conflicts of interest regarding the experimental part of this study."

"Funding This work was supported by funding from the Joint Program on Neurodegenerative Diseases (JPND) to SH and RM. (01ED1603). SH received further funding from the Sanofi Innovation Awards—Europe Program Funding Award (2018 iAward). CY-B and PB were supported by the Neuroscience School of Paris Foundation (ENP), the French Ministry of Higher Education and Research and the Association France Parkinson, respectively. The research leading to these results has received funding from the program “Investissements d’Avenir” ANR-10-IAIHU-06 and ANR-11-INBS-0011-NeurATRIS: Translational Research Infrastructure for Biotherapies in Neurosciences."